华海药业：下属子公司药物临床试验获美国FDA批准

Core Viewpoint - Huahai Pharmaceutical's subsidiary Huao Tai has received FDA approval to conduct Phase I clinical trials for the injectable drug HB0043, targeting pyogenic hidradenitis [1] Company Summary - Huahai Pharmaceutical (stock code: 600521) announced on September 17 that its subsidiary Huao Tai has obtained approval from the U.S. Food and Drug Administration (FDA) [1] - The drug HB0043 is indicated for the treatment of pyogenic hidradenitis [1] Industry Summary - The approval for HB0043 marks a significant step for Huahai Pharmaceutical in expanding its product offerings in the U.S. market [1] - The focus on pyogenic hidradenitis indicates a strategic move to address unmet medical needs within dermatological conditions [1]